:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/cloudfront-us-east-1.images.arcpublishing.com/gmg/52JJSQTVQZBTJFDRQDZVK4HJTU.jpg)
Eli Lilly’s antibody combination receives FDA emergency use authorization to treat COVID-19 patients
Read full article: Eli Lilly’s antibody combination receives FDA emergency use authorization to treat COVID-19 patientsFILE - This is an April 26, 2017, file photo showing Eli Lilly corporate headquarters in Indianapolis. Eli Lilly continues to back a potential COVID-19 treatment despite research showing that it may not work on hospitalized patients. The drugmaker said Tuesday, Oct. 27, 2020, that It remains confident that its drug may stop COVID from developing in other patients. (AP Photo/Darron Cummings, File)HOUSTON – Eli Lilly’s announced Tuesday the approval by the U.S. Food and Drug Administration (FDA) of Emergency Use Authorization (EUA) for its combination antibody therapy. Lilly will collaborate with the bio-tech company Amgen to manufacture up to one million doses of etesevimab for administration with bamlanivimab by mid-2021.
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/cloudfront-us-east-1.images.arcpublishing.com/gmg/GFGNHCRP2FAU3EOXH3S2E4YYXU.jpg)